Oridonin mitigates cerebral ischemic–reperfusion injury via covalent binding to HMGB1 and inhibiting the HMGB1/TLR4/MyD88/NF- κB signaling pathway

Abstract

Objective: Ischemic stroke (IS) is a leading cause of mortality and disability worldwide, and effective pharmacological treatments are limited. Oridonin (Ori) has demonstrated neuroprotective potential in IS; however, its underlying mechanisms are still poorly understood. Methods: In vitro, oxygen-glucose deprivation/reperfusion (OGD/R) models were established using mouse neuroblastoma Neuro-2a cells and primary cortical neurons. In vivo, a transient middle cerebral artery occlusion (tMCAO) model was induced in male C57BL/6J mice to simulate cerebral ischemic–reperfusion (I/R) injury. The key targets of Ori were identified using activity-based protein profiling (ABPP). The binding affinity between Ori and its target protein was validated using multiple approaches, including cellular thermal shift assay (CETSA), molecular docking, and biolayer interferometry (BLI). Results: Ori significantly suppressed the expression of inflammatory cytokines in tMCAO- and OGD/R-treated neuronal cells. Target identification revealed that high-mobility group box 1 (HMGB1) protein is the key mediator of the protective effects of Ori against cerebral I/R injury. Mechanistically, Ori covalently binds to cysteine (Cys) 106 of HMGB1, reducing its secretion and proinflammatory activity. Additionally, Ori downregulated cytoplasmic HMGB1 levels and the expression of TLR4 and MyD88, as well as the p-p65/p65 ratio in both OGD/R and tMCAO models. Notably, the HMGB1 inhibitor NecroX-7 conferred protection against OGD/R-induced neuronal injury and tMCAO-induced brain damage in mice, which could not be further modulated by Ori treatment. Conclusions: Our findings demonstrate that Ori confers neuroprotection against brain I/R injury by covalently binding to HMGB1 at Cys106 via its reactive carbon–carbon double bonds, thereby eliminating the proinflammatory activity of HMGB1. This molecular interaction reduces HMGB1 secretion and inhibits the downstream HMGB1/TLR4/MyD88/NF-κB signaling pathway, ultimately attenuating neuroinflammation and ischemic damage.

Keywords

Cerebral ischemic–reperfusion injury / Chemical proteomics / HMGB1 / Oridonin / Target discovery

References

[1] Vasu S, Luis G, Dileep RY. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology 2021; 97: S6-S16.

[2] Rabkin SW. Heart disease and stroke. Heart Mind 2023; 7(3): 115-116.

[3] Dmitry F, Alexander Z, Matthew B, et al. The development of novel drug treatments for stroke patients: a review. Int J Mol Sci 2022; 23(10): 5796.

[4] Shi K, Zou M, Jia DM, et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke. Circ Res 2021; 128(1): 62-75.

[5] Zhang M, Liu Q, Meng H, et al. Ischemia—reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther 2024; 9(1): 12.

[6] Alba S, Arthur L. Systemic inflammation after stroke: implications for post—stroke comorbidities. EMBO Mol Med 2022; 14(9): e16269.

[7] Shi K, Tian DC, Li ZG, et al. Global brain inflammation in stroke. Lancet Neurol 2019; 18(11): 1058-1066.

[8] Tian XD, Liu CL, Shu Z, et al. Therapeutic targeting of HMGB1 in stroke. Curr Drug Deliv 2016; 14(6): 785-790.

[9] Li JM, Wang ZX, Li JM, et al. HMGB1: a new target for ischemic stroke and hemorrhagic transformation. Transl Stroke Res 2024; 16(3): 990-1015.

[10] Tao T, Liu MZ, Chen MY, et al. Natural medicine in neuroprotection for ischemic stroke: challenges and prospective. Pharmacol Ther 2020; 216: 107695.

[11] Lin R, Lin X, Wu J, et al. Inhibitory effects of in esophageal squamous cell carcinoma: network pharmacology and experimental validation. Evid Based Complement Alternat Med 2022; 2022: 2696347.

[12] Guo S, Cui X, Jiang M, et al. Simultaneous characterization and quantification of 17 main compounds in Rabdosia rubescens by high performance liquid chromatography. J Food Drug Anal 2017; 25(2): 417-424.

[13] Xu JM, Wold EA, Ding Y, et al. Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection. Molecules 2018; 23(2): 474.

[14] Li X, Zhang CT, Ma W, et al. Oridonin: a review of its pharmacology, pharmacokinetics and toxicity. Front Pharmacol 2021; 12: 645824.

[15] Yan C, Yan H, Mao J, et al. Neuroprotective effect of oridonin on traumatic brain injury via inhibiting NLRP3 inflammasome in experimental mice. Front Neurosci 2020; 14: 557170.

[16] Greuel BK, Da Silva D, Robert—Gostlin V, et al. Natural compounds oridonin and shikonin exhibit potentially beneficial regulatory effects on select functions of microglia. Brain Sci 2024; 14(4): 328.

[17] Li L, Song JJ, Zhang MX, et al. Oridonin ameliorates caspase—9—mediated brain neuronal apoptosis in mouse with ischemic stroke by inhibiting RIPK3—mediated mitophagy. Acta Pharmacol Sin 2022; 44(4): 726-740.

[18] Liu DD, Luo P, Gu LW, et al. Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia—reperfusion. J Neuroinflammation 2021; 18(1): 174.

[19] Yang T, Liu DD, Li Y, et al. Chemoproteomics reveals sofalcone inhibits the inflammatory response of Caco—2 cells by covalently targeting HMGB1. Chem Commun (Camb) 2023; 59(58): 8981-8984.

[20] Guo QY, Wang QX, Chen JY, et al. Dihydroartemisinin regulated the MMP—mediated cellular microenvironment to alleviate rheumatoid arthritis. Research 2024; 7: 0459.

[21] Lu Y, Shen ZX, Xu YP, et al. Discovery of new phenyltetrazolium derivatives as ferroptosis inhibitors for treating ischemic stroke: an example development from free radical scavengers. J Med Chem 2024; 67(14): 11712-11731.

[22] Hwang IC, Kim JY, Kim JH, et al. Therapeutic potential of a novel necrosis inhibitor, 7—amino—indole, in myocardial ischemia—reperfusion injury. Hypertension 2018; 71(6): 1143-1155.

[23] Ugrinova I, Pasheva E. HMGB1 protein: a therapeutic target inside and outside the cell. Adv Protein Chem Struct Biol 2017; 107: 37-76.

[24] Venereau E, De Leo F, Mezzapelle R, et al. HMGB1 as biomarker and drug target. Pharmacol Res 2016; 111: 534-544.

[25] Paudel YN, Angelopoulou E, Piperi C, et al. HMGB1—mediated neuroinflammatory responses in brain injuries: potential mechanisms and therapeutic opportunities. Int J Mol Sci 2020; 21(13): 4609.

[26] Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.

[27] Shen LP, Yang JS, Zhu ZF, et al. Elevated serum HMGB1 levels and their association with recurrence of acute ischaemic stroke. J Inflamm Res 2024; 17: 6887-6894.

[28] Toshiyuki T, Ryu K, Mitsugu F, et al. Elevated serum high—mobility group box—1 protein level is associated with poor functional outcome in ischemic stroke. J Stroke Cerebrovasc Dis 2017; 26(10): 2404-2411.

[29] Owona BA, Schluesener HJ. Molecular insight in the multifunctional effects of oridonin. Drugs R D 2015; 15(3): 233-244.

[30] Liang L, Wang H, Hu Y, et al. Oridonin relieves depressive—like behaviors by inhibiting neuroinflammation and autophagy impairment in rats subjected to chronic unpredictable mild stress. Phytother Res 2022; 36(8): 3335-3351.

[31] Zhang ZY, Daniels R, Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med 2013; 17(12): 1566-1576.

[32] Wang SL, Yang H, Yu LJ, et al. Oridonin attenuates Aβ1—42—induced neuroinflammation and inhibits NF—κB pathway. PLoS One 2014; 9(8): e104745.

[33] Li L, Cheng SQ, Guo W, et al. Oridonin prevents oxidative stress—induced endothelial injury via promoting Nrf—2 pathway in ischaemic stroke. J Cell Mol Med 2021; 25(20): 9753-9766.

[34] Tang D, Kang R, Zeh HJ, et al. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol 2023; 23(12): 824-841.

[35] Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8(4): 195-202.

[36] Yu Y, Tang DL, Kang R. Oxidative stress—mediated HMGB1 biology. Front Physiol 2015; 6: 93.

[37] Andersson U, Tracey KJ, Yang H. Post—translational modification of HMGB1 disulfide bonds in stimulating and inhibiting inflammation. Cells 2021; 10(12): 3323.

[38] Ren W, Zhao L, Sun Y, et al. HMGB1 and Toll—like receptors: potential therapeutic targets in autoimmune diseases. Mol Med 2023; 29(1): 117.

[39] Le K, Mo S, Lu X, et al. Association of circulating blood HMGB1 levels with ischemic stroke: a systematic review and meta—analysis. Neurol Res 2018; 40(11): 907-916.

[40] E Y, Deng Q, Shi G, et al. The association between high mobility group box 1 and stroke—associated pneumonia in acute ischemic stroke patients. Brain Sci 2022; 12(11): 1580.

[41] Im KI, Kim N, Lim JY, et al. The free radical scavenger NecroX—7 attenuates acute graft—versus—host disease via reciprocal regulation of Th1/regulatory T cells and inhibition of HMGB1 release. J Immunol 2015; 194(11): 5223-5232.

[42] Singh V, Roth S, Veltkamp R, et al. HMGB1 as a key mediator of immune mechanisms in ischemic stroke. Antioxid Redox Signal 2016; 24(12): 635-651.

[43] Gao B, Wang SW, Li JF, et al. HMGB1, angel or devil, in ischemic stroke. Brain Behav 2023; 13(5): e2987.

[44] Nishibori M, Mori S, Takahashi HK. Anti—HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. J Pharmacol Sci 2019; 140(1): 94-101.

[45] Yang T, He YY, Huang MN, et al. Clinical study on the modulating effects of Jiaotaiwan on the microbiota—SCFAs—neurotransmitter/immune axis in patients with depression. Acupunct Herb Med 2025; 5(4): 456-468.